Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Haas

Showing results (601-610 of 645) with videos related to

Pageof 65
Sort By:
Infection Control and Hospital Epidemiology|July 16, 2014
Strategies to prevent healthcare-associated infections through hand hygieneKatherine Ellingson, Janet P Haas, Allison E Aiello, et al.
The Canadian Journal of Urology|April 21, 2011
Updating the prostate cancer risk indicator for contemporary biopsy schemesMeelan Bul, Nicolas B Delongchamps, Ewout W Steyerberg, et al.
The Journal of Urology|May 1, 1997
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockadeP F Schellhammer, P Venner, G P Haas, et al.
Infection Control and Hospital Epidemiology|November 8, 2014
Strategies to prevent healthcare-associated infections through hand hygieneKatherine Ellingson, Janet P Haas, Allison E Aiello, et al.
Prostate Cancer and Prostatic Diseases|October 8, 2021
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trialDavid F Penson, Andrew J Armstrong, Raoul S Concepcion, et al.
Prostate Cancer and Prostatic Diseases|December 1, 2021
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trialDavid F Penson, Andrew J Armstrong, Raoul S Concepcion, et al.
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
European Journal of Clinical Pharmacology|April 24, 2026
Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic explorationTomoki Kojima, Masako Saito, Toshihiro Matsuda, et al.
Journal of the American Society of Nephrology : JASN|February 24, 2004
Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndromeRainer G Ruf, Anne Lichtenberger, Stephanie M Karle, et al.
European Urology Oncology|December 10, 2023
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc AnalysisFrancisco Gomez-Veiga, Russell Z Szmulewitz, Jeffrey Holzbeierlein, et al.
Pageof 65

Showing results (601-610 of 645) with videos related to

Sort By:
Pageof 65
Infection Control and Hospital Epidemiology|July 16, 2014
Strategies to prevent healthcare-associated infections through hand hygieneKatherine Ellingson, Janet P Haas, Allison E Aiello, et al.
The Canadian Journal of Urology|April 21, 2011
Updating the prostate cancer risk indicator for contemporary biopsy schemesMeelan Bul, Nicolas B Delongchamps, Ewout W Steyerberg, et al.
The Journal of Urology|May 1, 1997
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockadeP F Schellhammer, P Venner, G P Haas, et al.
Infection Control and Hospital Epidemiology|November 8, 2014
Strategies to prevent healthcare-associated infections through hand hygieneKatherine Ellingson, Janet P Haas, Allison E Aiello, et al.
Prostate Cancer and Prostatic Diseases|October 8, 2021
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trialDavid F Penson, Andrew J Armstrong, Raoul S Concepcion, et al.
Prostate Cancer and Prostatic Diseases|December 1, 2021
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trialDavid F Penson, Andrew J Armstrong, Raoul S Concepcion, et al.
BJU International|August 16, 2014
Enzalutamide in European and North American men participating in the AFFIRM trialAxel S Merseburger, Howard I Scher, Joaquim Bellmunt, et al.
European Journal of Clinical Pharmacology|April 24, 2026
Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic explorationTomoki Kojima, Masako Saito, Toshihiro Matsuda, et al.
Journal of the American Society of Nephrology : JASN|February 24, 2004
Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndromeRainer G Ruf, Anne Lichtenberger, Stephanie M Karle, et al.
European Urology Oncology|December 10, 2023
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc AnalysisFrancisco Gomez-Veiga, Russell Z Szmulewitz, Jeffrey Holzbeierlein, et al.
Pageof 65